Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

617.45INR
21 Nov 2014
Price Change (% chg)

Rs-6.00 (-0.96%)
Prev Close
Rs623.45
Open
Rs621.90
Day's High
Rs625.90
Day's Low
Rs611.20
Volume
1,528,026
Avg. Vol
--
52-wk High
--
52-wk Low
--

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.59
Market Cap (Mil.): Rs264,700.00
Shares Outstanding (Mil.): 424.57
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): 463.18 38.05 39.20
EPS (TTM): 1.35 -- --
ROI: -- 17.86 17.16
ROE: -- 18.61 18.09
Search Stocks

U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs

Nov 20 - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

20 Nov 2014

Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

MUMBAI - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

18 Nov 2014

UPDATE 1-Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

* Ranbaxy alleges FDA's move violated constitutional rights

18 Nov 2014

Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

MUMBAI, Nov 18 - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

18 Nov 2014

UPDATE 2-India's Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

* Sun Q2 profit up 15 pct, roughly in line with street estimates

13 Nov 2014

U.S. pulls approval for Ranbaxy copies of AstraZeneca and Roche drugs

MUMBAI - The U.S. Food and Drug Administration (FDA) has revoked a tentative approval for India's Ranbaxy Laboratories Ltd to make a cheap copy of AstraZeneca Plc's heartburn drug Nexium, after its Indian plants were banned over quality control issues.

06 Nov 2014

UPDATE 2-U.S. pulls approval for Ranbaxy copies of AstraZeneca and Roche drugs

* Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte

06 Nov 2014

India's Ranbaxy loses six months exclusivity on Roche's antiviral drug

MUMBAI, Nov 6 - Indian drugmaker Ranbaxy Laboratories Ltd said the U.S. Food and Drug Administration has revoked the previously granted tentative approvals to the company for launching the first cheaper generic forms of AstraZeneca's heartburn drug Nexium and Roche's antiviral Valcyte.

06 Nov 2014

Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic: CEO

MUMBAI - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic -CEO

MUMBAI, Oct 28 - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Kisan Ratilal Choksey Shares and Securities Private Limited
$58.00
Provider: Motilal Oswal Securities Ltd.
$69.00
Provider: Axis Capital Limited
$35.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks